Increased S100B Levels in Cannabis Use Disorder.

Prior research has shown that cannabis use may affect brain health, but the specific biological indicators remain unclear. It was already known that S100B levels in blood may reflect neuronal damage in various conditions. No prior work had resolved whether cannabis use disorder specifically alters S100B concentrations. This gap motivated the need to examine S100B in cannabis users. That uncertainty drove the design of a comparative study between patients and controls. No prior work had tested S100B in cannabis use disorder populations. This uncertainty highlights the need to assess blood markers in substance use disorders. Understanding S100B's role could clarify the neurobiological impact of cannabis.

The aim was to compare S100B levels in individuals with cannabis use disorder and healthy controls. The specific problem was whether cannabis use might elevate S100B as a sign of brain damage. This study sought to address the lack of data on S100B in cannabis users. The motivation was to identify potential neurotoxic effects of cannabis. The researchers proposed that elevated S100B could indicate neuronal damage in these patients. This study aimed to test the hypothesis that cannabis use disorder alters S100B levels. The goal was to provide evidence linking cannabis use to possible brain injury. This study aimed to measure S100B in a clinical sample of cannabis users.

The study design involved comparing S100B levels in two groups: cannabis users and controls. Blood samples were collected from participants for S100B measurement. An electrochemiluminescence immunoassay was used to quantify S100B. The sample size included 32 patients and 31 controls matched for age and sex. Serum concentrations were analyzed for statistical significance. The primary outcome was the mean S100B level in each group. The study used a cross-sectional approach to assess differences. Data were analyzed using standard statistical tests to determine significance.

The strongest finding was that cannabis users had higher S100B levels than controls. The mean S100B concentration was 0.081 ± 0.018 μg/l in cannabis users. Controls had a mean of 0.069 ± 0.018 μg/l, with a p-value of 0.008. This difference suggests a statistically significant elevation in users. The study found no other significant differences between groups. No other biomarkers were measured in this study. The results support the idea that cannabis use may elevate S100B. These findings may indicate neuronal damage in cannabis users.

The authors suggest that elevated S100B levels may reflect neuronal damage in cannabis users. The study found a significant difference between cannabis users and controls. This result supports the hypothesis that cannabis use may affect brain health. The researchers propose that S100B could serve as a potential biomarker. No prior work had shown this specific link in cannabis use disorder. The study does not claim that cannabis causes irreversible damage. These findings may help identify neurotoxic effects in users. The authors suggest further research to confirm these results.